|
Synonyms: B2036-PEG | Somavert®
pegvisomant is an approved drug (FDA (2003), EMA (2008))
Compound class:
Peptide or derivative
Comment: Pegvisomant is a PEGylated 191 amino acid protein analogue of growth hormone, with antagonist action at the growth hormone receptor. The peptide sequence can be obtained via the ChEMBL link. PEGylation protects the peptide from proteolytic breakdown and extends its bioactive half-life.
|
| No information available. |
Summary of Clinical Use  |
| Approved to treat acromegaly which has not been controlled by other interventions (eg surgery, radiation therapy or somatostatin treatment). |
| Mechanism Of Action and Pharmacodynamic Effects |
| Pegvisomant inhibits the ability of endogenous growth hormone to interact with the growth hormone receptor, the aim of which is to normalize serum IGF-I levels in acromegalic patients [1]. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
